BRAF and neoplasm: Overall, we did not demonstrate a significant association between BRAF (V600E) mutation and the remaining clinicopathological characteristics of PTC, which included sex, tumour size, histological subtype, multifocality, ETE, vascular invasion, lymph node and distant metastases, as well as intermediate/high risk to recurrence according to current guidelines.